FDA Approves COLUMVI — Genentech, Inc.

Genentech, Inc. received FDA approval in June 2023 for its intravenous antibody drug Glufitamab under the brand name COLUMVI, a significant milestone for the company’s portfolio of hematologic oncology therapeutics. The approval of this Chimeric Antigen Receptor T cell (CAR) therapy is poised to expand the competitive landscape for large B-cell malignancies and bolster Genentech's market positioning in the high-growth CAR-T and bispecific antibody sectors.